<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical settings and anticoagulants that may interfere with testing for thrombophilia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical settings and anticoagulants that may interfere with testing for thrombophilia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical settings and anticoagulants that may interfere with testing for thrombophilia</div><div class="cntnt"><table cellspacing="0"><colgroup width="40%"></colgroup><colgroup span="4" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Thrombophilic disorder</td> <td class="subtitle1" colspan="4">Clinical settings and anticoagulants</td> </tr> <tr> <td class="subtitle2">Acute thrombosis</td> <td class="subtitle2">Heparin therapy</td> <td class="subtitle2">Warfarin</td> <td class="subtitle2">Direct oral anticoagulants*</td> </tr> <tr> <td>Factor V Leiden</td> <td>NC</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td>Prothrombin G20210A</td> <td>NC</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td>Protein C (PC) deficiency</td> <td>NC</td> <td>NC</td> <td>Cannot measure<sup>¶</sup></td> <td>Cannot measure using functional assays<sup>Δ</sup></td> </tr> <tr> <td>Protein S (PS) deficiency</td> <td>Can be lowered<sup>◊</sup></td> <td>NC</td> <td>Cannot measure<sup>¶</sup></td> <td>Cannot measure using functional assays<sup>Δ</sup></td> </tr> <tr> <td>Antithrombin (AT) deficiency</td> <td>Can be lowered<sup>◊</sup></td> <td>Lowered</td> <td>NC</td> <td>Cannot measure using functional assyas<sup>Δ</sup></td> </tr> <tr> <td>Antiphospholipid antibodies</td> <td>NC</td> <td>NC</td> <td>NC</td> <td>NC</td> </tr> <tr> <td>Lupus anticoagulant<sup>§</sup></td> <td>NC</td> <td>Cannot measure<sup>Δ</sup></td> <td>False positives possible</td> <td>Cannot measure<sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Increased factor VIII activity</td> <td class="centered" colspan="4">Acute phase reactant. Do not test while inflammation is still present.</td> </tr> <tr> <td colspan="5"><strong>Acquired AT deficiency:</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="5">Neonatal period; pregnancy; liver disease; DIC; nephrotic syndrome; major surgery; acute thrombosis; treatment with L-asparaginase, heparin, or estrogens</td> </tr> <tr> <td colspan="5"><strong>Acquired protein C deficiency:</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="5">Neonatal period; liver disease; vitamin K deficiency; DIC, chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil; inflammation; treatment with warfarin or L-asparaginase</td> </tr> <tr> <td colspan="5"><strong>Acquired protein S deficiency:</strong></td> </tr> <tr> <td class="indent1" colspan="5">Neonatal period; pregnancy; liver disease; vitamin K deficiency; DIC; treatment with warfarin, L-asparaginase, or estrogens</td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate topics on the specific hypercoagulable disorders for additional information. If a result is abnormal in a patient receiving an anticoagulant, it may be prudent to repeat the test in the absence of the anticoagulant, if possible.</div><div class="graphic_footnotes">NC: not changed; LMW heparin: low molecular weight heparin; AT: antithrombin; DIC: disseminated intravascular coagulation.<br/>* Direct oral anticoagulants (DOACs) include dabigatran, apixaban, edoxaban, and rivaroxaban.<br/>¶ If it is important to test for these deficiencies while the patient is still anticoagulated, switch the treatment to full-dose heparin or LMW heparin and discontinue warfarin for at least 2 weeks before measurement. Comparing protein S or C levels with prothrombin antigen in stably anticoagulated patients is not reliable, as accurate measurement of prothrombin antigen levels is a research assay that is not generally available.<br/>Δ Some laboratories can perform testing if they use a reagent to inactivate or remove the anticoagulant (heparinase for heparin, activated charcoal for DOACs). Some functional assays for protein C, protein S, and AT deficiency are not subject to interference by DOACs.<br/><span class="lozenge">◊</span> Results for protein S and AT can be affected by acute thrombosis; it is most cost effective to avoid testing during the initial presentation. However, if plasma levels are well within the normal range at presentation, deficiency is essentially excluded.<br/>§ Lupus anticoagulant testing should only be done in the absence of any anticoagulant, as it is a clot-based test. However, antiphospholipid antibodies can be tested because they are serologic assays and are unaffected by anticoagulation.</div><div id="graphicVersion">Graphic 76966 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
